Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative

Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders.

The initiative aims to address underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Silo Pharma’s portfolio includes innovative programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The company conducts research in collaboration with leading universities and laboratories.

This move into ibogaine-based therapeutics represents a significant expansion of Silo’s pipeline. Ibogaine, a naturally occurring psychoactive alkaloid, has shown potential in treating addiction and mood disorders, but its application for TBI is novel. The provisional patent filing indicates Silo’s commitment to protecting its intellectual property in this emerging field.

Traumatic brain injury is a major public health issue, with millions of cases annually in the U.S. alone. Current treatments are limited, and there is a high unmet need for effective therapies. Silo Pharma’s initiative could potentially offer new hope for patients suffering from TBI and its long-term consequences, including PTSD and other neuropsychiatric conditions.

The company’s diversified portfolio also includes a cryptocurrency treasury component, though its primary focus remains on biopharmaceutical development. Silo’s strategy of targeting underserved conditions positions it to address significant gaps in the market.

For more information, visit silopharma.com. The full press release is available at https://ibn.fm/HdWHG. Updates on SILO can be found in the company’s newsroom at https://ibn.fm/SILO.

This announcement underscores the growing interest in psychedelic-derived therapies for neurological conditions. As research progresses, Silo Pharma’s initiative could contribute to the development of new treatment paradigms for TBI and related disorders.